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Neoadjuvant chemoradiation (CRT) followed by curative surgery still remains the standard of care for locally advanced rectal cancer
(LARC).Themain purpose of this multimodal treatment is to achieve a complete pathological tumor response (ypCR), with better
survival. The surgery delay after CRT completion seems to increase tumor response and ypCR rate. Usually, time intervals range
from 8 to 12 weeks, but the maximum tumor regression may not be seen in rectal adenocarcinomas until several months after CRT.
About this issue, we report a case of a 52-year-old man with LARC treated with neoadjuvant CRT who developed, one month after
RT completion, an acute myocardial infarction. The need to increase the interval between CRT and surgery for 17 weeks allowed a
curative surgery without morbidity and an unexpected complete tumor response in the resected specimen (given the parameters
presented in pelvic magnetic resonance imaging (MRI) performed 11 weeks after radiotherapy completion).
1. Introduction
Neoadjuvant chemoradiation (CRT) followed by total
mesorectum excision (TME) surgery and systemic
chemotherapy still remains the standard of care for
locally advanced rectal cancer (LARC), but not all cases
benefit from this treatment modality. This multimodal
treatment improves disease pelvic control but better survival
is achieved only if pathological response is present [1, 2].
In LARC, neoadjuvant CRT is extensively used to decrease
the risk of local failure by sterilizing microscopic tumor foci
not removed by the surgeon. It also allows radical surgery
in difficult resectable tumors and increases the chances
of sphincter-saving surgery. For a successful outcome, the
size or the stage of the rectal tumor must be decreased. An
interval between the end of CRT and surgery is required
for tumor regression. Moreover, tumor regression varies
between complete, poor, and even absence response. Tumor
regression grade depends on tumor biology, CRT scheme,
and the time interval between the end of CRT and surgery.
If tumor response is complete or near complete, we have a
favorable tumor biological profile with less risk of recurrence
and better survival. When tumor CRT response is present,
prolonging the time interval between CRT and surgery in
order to achieve maximal tumor regression and diminish
complications during surgery is advisable. On the other
hand, if the tumor is a poor responder, a longer time interval
after CRT is counterproductive. Maximum tumor regression
may not be seen in rectal adenocarcinomas until after several
months after the end of CRT; thus, a longer than usual CRT
delay may benefit those well responding tumors. Predicting
tumor response is not possible yet and the delay between
neo-CRT and surgery in most studies ranges between 8 and
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Figure 1: Diagnosis and staging. (a) Rectal biopsy mucinous adenocarcinoma; (b), (c), (d), (e), and (f) CT scan large tumor with 9 cm of
longitudinal length and 7 cm of transverse diameter, plan between tumor and prostate not evident, multiple enlarged pelvic lymph nodes,
and no evidence of inguinal nodal involvement or distant metastasis.
12 weeks. The optimal interval time between neoadjuvant
CRT and surgery for rectal cancer has been debated.
In this regard we report a patient with LARC where the
need to increase the interval between neo-CRT and surgery
in 17 weeks was safe and allowed a complete tumor response
in the resected specimen that was not present in the pelvic
MRI performed 11 weeks after radiotherapy completion.
2. Case Report
A 52-year-old man, with a 4-month history of bloody stool,
change in size and shape of stools, and feeling of incomplete
defecation, is subjected to a colonoscopy that revealed ulcer
vegetative circumferential tumor at 6 cm of anal margin not
crossable with colonoscope. Biopsy resulted in ulcerative
adenocarcinoma (Figure 1(a)).
Physical examination confirmed ulcerative circular
lesion, fixed with lower edge at 6 cm of anal margin, without
enlarged inguinal lymph nodes. CT scan (Figures 1(b),
1(c), and 1(d)) and MRI (Figures 2(a), 2(b), and 2(c))
revealed a large tumor with 9 cm of longitudinal length and
7 cm of transverse diameter that extended to left side of
mesorectal fascia, multiple enlarged pelvic lymph nodes,
and no evidence of inguinal nodal involvement or distant
metastasis.
Tumor staging was T4N+M0. Laboratory data showed
a normal carcinoembryonic antigen serum level. Before
initiating therapy, a laparoscopic colostomy was performed
to avoid bowel obstruction. Neoadjuvant chemoradiotherapy
was given: a total irradiation of 50.4Gy in 28 fractions
and capecitabine 825mg/m2 (five weeks). CRT progressed
uneventfully but, four weeks after the end of RT, the patient
had an acute myocardial infarction requiring coronary stents
and dual antiplatelet therapy. For this reason, surgery planned
for 8 weeks after the end of RT was delayed. In the meantime,
11 weeks after RT completion a restagingMRIwas performed.
The size of rectal tumor had dramatically diminished,
with tumor downstaging and increased mesorectal distance.
Nonetheless, there were still some small nodular areas at the
periphery of the posterior margin of the rectum that were
suspicious for residual tumor (Figures 3(a), 3(b), and 3(c)).
17 weeks after radiotherapy the patient cardiac function
recovered, and a radical surgical resection was performed.
A conventional ultralow anterior rectal resection, with total
mesorectum excision, was performed after colostomy closure
by open access (Figures 4(a), 4(b), and 4(c)).
Bowel transit reestablishment was carried out by a
coloanal end-to-end anastomosis. A diverting ileostomy was
placed in the previous colostomy site. The postoperative
course was uneventful and the patient was discharged from
hospital 7 days after surgery. The resected specimen revealed
mucin pools but no malignant epithelium, complete patho-
logical response. In order to ensure the absence of epithelial
cells within the mucin pools, the entire area containing
macroscopic alteration was submitted to histopathological
and immunohistochemistry analysis (Figures 4(c) and 4(d)).
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Figure 2:MRI beforeCRT. Large tumorwith 9 cmof longitudinal length and 7 cmof transverse diameter that extends to left side ofmesorectal
fascia, multiple enlarged pelvic lymph nodes. Thin arrow: metastatic lymph node; thick arrow: mesorectal fascia invasion.
(a) Axial plan (b) Coronal plan
Figure 3: MRI 11 weeks after CRT completion. Good tumor response: tumor downsizing and downstaging, nodal downstaging, and
increase between tumor and mesorectal fascia. Thin arrow: areas of fibrosis (very low signal intensity); thick arrow: areas of residual tumor
(intermediate signal intensity).
The ileostomy closure was performed 6 weeks after rectal
surgery.
3. Discussion
The achievement of ypCR is the ultimate goal of LARC
therapeutic with neoadjuvant RCT. When present, ypCR
implies a better survival and delaying radical surgery and
adopting a “wait and see” strategymight be appropriate when
the patient is unfit because of comorbidities or is unwilling to
undergo radical surgery.
Two major problems remain: rates of low ypCR and
difficulty in defining clinical complete response (cCR) at
restaging MRI, after completion of CRT.
Only ypCR rates of 13–30% have been reported in phase
II and phase III trials following 5FU based preoperative
CRT. A way to increase this rate is delaying the interval
between neoadjuvant CRT and surgery. The optimal interval
remains debatable. In 1999, Francois et al. [3] compared short
(within 2 weeks) and long (6 to 8 weeks) interval groups
following preoperative radiotherapy (RT) and showed that
longer intervals were associated with better clinical tumor
response, pathological downstaging, and a nonsignificant
trend towards increased sphincter preservation. They sug-
gested that a longer interval may increase the chance of
successful sphincter-saving surgery through improved tumor
response. The increased intervals could potentially increase
the tumor downstaging effect as the radiation-induced necro-
sis appears to be a time-dependent phenomenon. As a
consequence, this 6- to 8-week interval has become part of
the standard protocol for the treatment of mid and low rectal
cancer. Recently, several studies including a meta-analysis
suggested that this interval can be further expanded (8- to 12-
week) with higher rates of pCR and downstaging, decreased
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Figure 4: Resected specimen and histological result. (a) Resected specimen; (b) and (c) details of resected specimen; (d) mucin pools with
histiocytes in muscular layer but no malignant epithelium; (e) and (f) immunohistochemistry analysis with cytokeratin AE1/AE3 confirms
the absence of malignant epithelium.
recurrence, and improved DFS [4–6]. Based on these studies,
in last 12 years, our institution adopted the mean interval
of 8 weeks without more anastomotic complications [7].
Intervals longer than 12 weeks are not recommended. There
is a potential risk of emergence of subclinical tumors which
can grow more rapidly than the primary tumor and increase
risk of developing distant metastases [8, 9]. Also, fibrosis that
could be establishedmay lead to surgical technical difficulties,
with increased morbidity.
Emerging evidence has shown the prognostic impor-
tance of reassessing rectal cancers using high-resolution
T2-weighted MRI after completion of CRT [10–12]. These
reassessment MRIs have implications in surgical planning,
timing of surgery, sphincter preservation, deferral of surgery
for good responders, and development of further preoper-
ative treatments for imaging poor responders. It should be
stressed however that MRI findings depend on the ability to
differentiate the tumor from posttreatment fibrosis besides
the MRI timing. On post-CRT T2-weighted MR imaging, we
found that areas of fibrosis have very low signal intensity,
whereas areas of residual tumor have intermediate signal
intensity, which can be difficult to interpret. In the last two
years, our institution performed MRI in LARC treated with
neoadjuvant CRT restaging, 6 weeks after CRT completion.
In our case report, posttreatment MRI was realized 11
weeks after CRT completion and revealed a good response
to treatment, but not a complete response. Post-CRT T2-
weighted MRI showed areas of intermediate signal intensity
that were interpreted as residual tumor. Delaying surgery
for 17 weeks afforded an unexpected complete pathological
response: tumor response was prolonged beyond 11 weeks.
On the other hand, contrary to expectations, this did not
lead to an increased difficulty in surgery or an increased
morbidity.
Delaying surgery more than 12 weeks in patients with
good response to CRT does not seem to have a negative
impact on patients prognosis: this is valid in ypCR, in
accordance with “wait and see policy” [13, 14] but must be
confirmed in patients with partial response to CRT.
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